Hydrea, Hydroxyurea Newswire

Comprehensive Real-Time News Feed for Hydrea, Hydroxyurea (generic).

Results 1 - 20 of 93 in Hydrea, Hydroxyurea (generic)

  1. Incyte Corporation Announces Top-Line Results From RELIEF Trial Of...Read the original story

    Thursday Jul 24 | BioSpace

    Incyte Corporation today announced top-line results from RELIEF, a randomized, double-blind clinical trial designed to compare symptom improvement in 110 patients with polycythemia vera treated with ruxolitinib versus patients treated with hydroxyurea .


  2. Incyte's Jakafi fails label expansion trialRead the original story

    Wednesday Jul 23 | Seeking Alpha

    In a 110-patient, randomized, double-blind Phase 3 clinical trial comparing Incyte Corp.'s Jakafi to hydroxyurea as a treatment for polycythemia vera , the JAK inhibitor failed to achieve its primary endpoint of a statistically significant proportion of patients with a 50% reduction in a defined cluster of symptoms versus baseline at Week 16.


  3. Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia VeraRead the original story

    Wednesday Jul 23 | Business Wire

    Statistical significance not achieved for the primary endpoint of symptom control; positive trends in favor of ruxolitinib versus hydroxyurea observed RELIEF trial conducted in patients who were generally well-controlled on hydroxyurea but reporting continued disease-related symptoms, a different population than the pivotal Phase III RESPONSE trial ... (more)


  4. Case report: a 37-year-old male with telangiectasias, polycythemia...Read the original story

    Tuesday Jul 22 | BioMed Central

    The TEMPI syndrome was recently described in 2011, and is characterized by the constellation of five hallmarks: Telangiectasias, Erythrocytosis and elevated Erythropoietin, Monoclonal gammopathy, Perinephric fluids collections, and Intrapulmonary shunting.


  5. Choice Behavior of Drosophila Facing Contradictory Visual CuesRead the original story

    Sunday Jul 20 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.


  6. African American blood donors neededRead the original story w/Photo

    Monday Jul 14 | The Charlotte Observer

    Dr. Ify Osunkwo, specialist in hematology and sickle cell disease at Levine Cancer Institute, in Carolinas HealthCare System.


  7. First drug candidate from NIH program acquired by biopharmaceutical companyRead the original story w/Photo

    Wednesday Jul 9 | PhysOrg Weblog

    A drug candidate developed by researchers at the NIH's National Center for Advancing Translational Sciences and its collaborators to treat sickle cell disease has been acquired by Baxter International's BioScience business.


  8. One day, science may cure sickle cell anaemiaRead the original story w/Photo

    Wednesday Jul 9 | PhysOrg Weblog

    A child in Senegal waiting to be tested for sickle cell anaemia - in parts of Africa up to 40% of the population can carry the sickle cell gene.


  9. PARG is dispensable for recovery from transient replicative stress...Read the original story

    Thursday Jul 3 | Nucleic Acids Research

    To whom correspondence should be addressed. Tel: +33 3 68 85 47 04; Fax: +33 3 68 85 46 83; Email: The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.


  10. Less Toxic Transplant Treatment Offers Hope for Sickle Cell PatientsRead the original story w/Photo

    Wednesday Jul 2 | MedicineNet

    A new bone marrow transplant technique for adults with sickle cell disease may "cure" many patients.


  11. sickle cell diseaseRead the original story

    Aug 11, 2010 | InteliHealth

    Hemoglobin is a protein in red blood cells that carries oxygen. People with sickle cell anemia inherit a defective type of hemoglobin.


  12. Marrow transplants can reverse adult sickle cellRead the original story w/Photo

    Tuesday Jul 1 | KFVS12

    CHICAGO - Bone marrow transplants can reverse severe sickle cell disease in adults, a small study by government scientists found, echoing results seen with a similar technique used in children.


  13. Mast Therapeutics' MST-188 Would Fit Well In Merck's Drug Development PipelineRead the original story

    Jun 24, 2014 | Seeking Alpha

    Acquiring Mast Therapeutics would provide Merck with a competitor to Pfizer's sickle cell drug being developed and licensed through GlycoMimetics.


  14. World Sickle Cell Day 2014: Why Raising Awareness About This Condition MattersRead the original story w/Photo

    Jun 19, 2014 | Medical Daily

    Sickle Cell Day is meant to raise awareness about the disease that still has no cure and affects millions of children under the age of 5 all over the world.


  15. Icon for FDA Voice blog post.Read the original story w/Photo

    Jun 12, 2014 | US Food and Drug Administration

    Today is a World Sickle Cell Awareness Day, an annual reminder that Sickle Cell Disease is a major area of unmet medical need that causes serious and devastating consequences to many thousands of children and adults.


  16. New drug helps to relieve pain, prolongs life for kids with sickle cellRead the original story w/Photo

    Jun 18, 2014 | WSFA-TV Montgomery

    It's also painful and results in many hospital visits for 3-year-old Nyla and 6-year-old Blake Ballentine.


  17. The Drosophila Werner Exonuclease Participates in an...Read the original story

    Jun 17, 2014 | Genetics current issue

    Members of the RecQ family of helicases are known for their roles in DNA repair, replication, and recombination.


  18. UV-B inhibition of hypocotyl growth in etiolated Arabidopsis thaliana ...Read the original story

    Jun 13, 2014 | Journal of Experimental Botany

    Ultraviolet radiation is an important constituent of sunlight that determines plant morphology and growth.


  19. Piper Jaffray biopharm analyst holds an analyst/industry conference callRead the original story

    May 29, 2014 | Theflyonthewall.com

    Novartis, Incyte announce results from RESPONSE trial evaluating ruxolitinib Novartis and Incyte announced results from the first-ever pivotal Phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera.


  20. Human single-stranded DNA binding protein 1 (hSSB1/NABP2) is required ...Read the original story

    Jun 2, 2014 | Nucleic Acids Research

    Human single-stranded DNA binding protein 1 is required for the stability and repair of stalled replication forks a Correspondence may also be addressed to Kum Kum Khanna.